Erythrocyte membrane coated nanoparticle-based control releasing hydrogen sulfide system protects ischemic myocardium.

Nanomedicine (London, England) Pub Date : 2021-03-01 Epub Date: 2021-02-18 DOI:10.2217/nnm-2020-0404

Kai Huang, Shuyan Wen, Wenshuo Wang, Jing-E Zhou, Jiechun Huang, Fangrui Wang, Liewen Pang, Yiqing Wang, Xiaotian Sun

{"title":"Erythrocyte membrane coated nanoparticle-based control releasing hydrogen sulfide system protects ischemic myocardium.","authors":"Kai Huang, Shuyan Wen, Wenshuo Wang, Jing-E Zhou, Jiechun Huang, Fangrui Wang, Liewen Pang, Yiqing Wang, Xiaotian Sun","doi":"10.2217/nnm-2020-0404","DOIUrl":null,"url":null,"abstract":"Aim: To construct a long circulatory and sustained releasing H2S system and explore its protective effects on myocardial ischemia and reperfusion (I/R) injury. Materials & methods: Red blood cell (RBC) membrane-coated, diallyl trisulfide (DATS)-carrying mesoporous iron oxide nanoparticles (MIONs) (RBC-DATS-MIONs) were prepared and characterized. Cytotoxicity and cellular uptake were studied in vitro, followed by in vivo assessment of safety, distribution and effect on cardiac function following I/R injury. Results: RBC-DATS-MIONs exhibited excellent biocompatibility, extended circulatory time and controlled-release of H2S in plasma and myocardium. They exhibited superior therapeutic effects on in vitro hypoxia/reoxygenation models and in vivo myocardial I/R models, which involved various mechanisms, including anti-apoptosis, anti-inflammatory and antioxidant activities. Conclusion: This work provides a new potential platform for best utilizing the protective effects of H2S by prolonging its releasing process.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/nnm-2020-0404","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/2/18 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 7

Abstract

Aim: To construct a long circulatory and sustained releasing H₂S system and explore its protective effects on myocardial ischemia and reperfusion (I/R) injury. Materials & methods: Red blood cell (RBC) membrane-coated, diallyl trisulfide (DATS)-carrying mesoporous iron oxide nanoparticles (MIONs) (RBC-DATS-MIONs) were prepared and characterized. Cytotoxicity and cellular uptake were studied in vitro, followed by in vivo assessment of safety, distribution and effect on cardiac function following I/R injury. Results: RBC-DATS-MIONs exhibited excellent biocompatibility, extended circulatory time and controlled-release of H₂S in plasma and myocardium. They exhibited superior therapeutic effects on in vitro hypoxia/reoxygenation models and in vivo myocardial I/R models, which involved various mechanisms, including anti-apoptosis, anti-inflammatory and antioxidant activities. Conclusion: This work provides a new potential platform for best utilizing the protective effects of H₂S by prolonging its releasing process.

查看原文本刊更多论文

红细胞膜包被纳米颗粒控制硫化氢释放系统对缺血心肌的保护作用。

目的:构建长循环缓释H2S系统，探讨其对心肌缺血再灌注(I/R)损伤的保护作用。材料与方法:制备了包被红细胞(RBC)膜、携带三硫二烯丙基(DATS)的介孔氧化铁纳米颗粒(RBC-DATS-MIONs)并对其进行了表征。体外研究细胞毒性和细胞摄取，然后在体内评估I/R损伤后的安全性、分布和对心功能的影响。结果:RBC-DATS-MIONs具有良好的生物相容性，延长循环时间，可在血浆和心肌中控制H2S的释放。它们对体外缺氧/再氧化模型和体内心肌I/R模型均有良好的治疗作用，其作用机制包括抗凋亡、抗炎和抗氧化等。结论:通过延长H2S的释放过程，为充分利用H2S的保护作用提供了一个新的潜在平台。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nanomedicine (London, England)

自引率

0.00%

发文量